$ULBI

Ultralife Corporation Reports Second Quarter Results

ULTRALIFE CORP (ULBI) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Ultralife Corporation Reports Second Quarter Results NEWARK, N.Y. – August 7, 2026 -- Ultralife Corporation (NASDAQ: ULBI) reported operating results for the second quarter ended June 30, 2026 with the following results: ● Sales of $47.9 million compared to $48.6 mil

Original reporting
Published Aug 7, 2026, 8:01 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 7, 2026, 8:07 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$ULBI
Bullish
medium confidence
Mentioned
$ULBI
Relevance
7/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$ULBIBullishMed
01

Why it matters

Traders can update near-term expectations based on the reported margin expansion, adjusted EBITDA improvement, segment mix shift (Communications Systems up 39.3%), and record backlog of $117.5M.

02

Market read

The filing provides fresh, decision-relevant datapoints for ULBI: profitability improvement, segment growth, and backlog at the highest level in the company’s history.

03

What to watch

Operating expenses rose as a share of revenue, and the company cited litigation-related one-time costs tied to a cyber-insurance claim, which could complicate forward earnings quality.

Relevance 7/10Novelty 8/10Timing: after-hours filing of Q2 results on Aug 7, 2026

Background

This is an SEC 8-K with Exhibit 99.1 reporting Ultralife’s second quarter 2026 results and financial condition.

Company-level read

Ticker impact

$ULBIBullishMedium confidence
Context

Ultralife reported Q2 revenue of $47.9M, GAAP EPS $0.15, and gross margin 28.9%, including a $1.1M IEEPA refund.

Expected impact

Near-term bias to the upside if investors focus on gross margin and backlog record, but tempered by flat-to-down revenue and higher opex.

Evidence & confidence

The filing provides multiple concrete profitability metrics (gross margin, operating income, adjusted EBITDA) plus segment mix changes and a record backlog, which typically drive earnings revisions and sentiment for small/mid-cap industrials.

Market effects

Signals improving manufacturing efficiency and defense-related product pipeline execution for battery and communications systems suppliers.

Limited direct regional read-through; primarily company-specific profitability and backlog signal.

Defense/government program timing and tariff-related refunds (IEEPA) highlight cross-border policy sensitivity for industrial suppliers.

Counterpoint

Gross margin improvement is partly driven by a one-time IEEPA refund, so normalized margins may be less strong than headline profitability suggests.

Key entities

  • Ultralife Corporation

    Reports Q2 2026 results, including gross margin expansion and record backlog, and discusses manufacturing efficiency initiatives and product pipeline.

  • Mike Manna

    CEO quoted on margin improvement initiatives and expected revenue transitions later in 2026.

Related articles

$ENSHighAI 9/10

EnerSys to Acquire Ultralife for $16 Per Share in Cash

EnerSys (ENS) agreed to acquire Ultralife for $16 per share in cash. The deal, subject to regulatory approvals, includes support from shareholders holding 40.3% of Ultralife's shares. The tender offer is expected to start within 10 business days and may close by April 27, 2027, with possible extensions.

$ENSHighAI 9/10

EnerSys to acquire Ultralife for $320 million in cash

EnerSys (ENS) agreed to acquire Ultralife (ULBI) for $320 million in cash, including debt. Ultralife shareholders will receive $16.00 per share, a 166% premium over Monday's closing price. The deal, approved by both boards, is expected to close in Q1 2027. EnerSys will finance the acquisition with available cash. Both companies' CEOs cited strategic benefits and value creation.

$ULBIMedAI 8/10

Ultralife (ULBI) Q2 2026 Earnings Call Transcript

Ultralife (ULBI) reported Q2 FY2026 revenue of $47.9 million, down 1.3% year over year, with GAAP EPS of $0.15. Gross margin rose to 28.9% on a 500 bps increase, aided by a $1.1 million IEEPA tariff refund. Backlog hit a record $117.5 million, up 39% from a year earlier, and July backlog neared $130 million.